Dr. Weber is deputy director for the Laura and Isaac Perlmutter Cancer Center, and is head of experimental therapeutics and professor of medicine at New York University’s Langone Medical Center in New York City. His research interests lie in the monitoring and characterization of T cell responses to immunotherapeutic treatments in cancer patients, and in the establishment of in vitro models to facilitate the understanding of how immune modulating antibodies amplify T cell responses in patients. He is also interested in the mechanisms by which achieving autoimmunity induces regression of cancer. His clinical interests are in the immunotherapy of melanoma and other malignancies, with a focus on adoptive immunotherapy, epigenetic therapy and the use of immune modulating antibodies.
Dr. Weber is the principal investigator of several ongoing studies funded by the National Cancer Institute, including trials in clinical drug development and managing the autoimmune side effects of immunotherapy for melanoma. He has served as principal investigator and director of the Moffitt Cancer Center’s Specialized Programs of Research Excellence (SPORE) grant for skin cancer and melanoma research from the National Cancer Institute.
He has published more than 150 articles in top peer-reviewed journals, and sits on the scientific advisory boards of cancer-related biotechnology companies and numerous cancer institutions and foundations.
Dr. Weber received his medical degree from New York University and his Ph.D. from Rockefeller University.